Treatment-experienced HIV Patients With High CD4+ Cell Counts Switched To Viramune® (nevirapine) Tablets Less Likely To Discontinue Therapy

... New data from a retrospective analysis of the EuroSIDA cohort show that treatment-experienced HIV-infected patients with high CD4+ cell counts who switched to a combination treatment regimen containing Viramune® had a lower risk of discontinuing therapy due to toxicities or patient/physician choice (TOXPC) than treatment-naïve HIV-infected patients with similar CD4+ cell counts. [click link for full article] ...